ESSA PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.08 USD | -0.65% |
|
-3.80% | -7.88% |
| Mar. 06 | Transcript : ESSA Pharma Inc. - Shareholder/Analyst Call | |
| Mar. 06 | Norway's wealth fund pushes for more women on emerging market company boards | RE |
Presenter SpeechKalpit Patel (Analysts)All right. Our next company for a fireside chat is ESSA...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
Calendar
2024-05-06
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
8.323
CAD
Average target price
27.08
CAD
Spread / Average Target
+225.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.88% | 269M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- EPIX Stock
- News ESSA Pharma Inc.
- Transcript : ESSA Pharma Inc. Presents at B. Riley Securities' 3rd Annual Oncology Conference, Jan-19-2023 11
